11th Apr 2025 07:00
Bioventix plc("Bioventix" or the "Company")
Option Exercise, Director/PDMR Shareholding, and Total Voting Rights
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, was notified on 10 April 2025 that 5,204 options were exercised over its ordinary shares of 5 pence each ("Ordinary Shares") by Peter Harrison, Chief Executive Officer, at a price of 1,350 pence per Ordinary Share.
Following this transaction, Mr Harrison's holding in the Company is as detailed below:
Director
| Number of options exercised | Number of options held post exercise | Number of Ordinary Shares post-exercise held | Resulting interest in fully diluted share capital % |
Peter Harrison | 5,204 | 19,811 | 302,292 | 5.79% |
Application will be made for 5,204 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to become effective on 16 April 2025. Following Admission, the Company will have 5,224,860 Ordinary Shares in issue. All Ordinary Shares shall have equal voting rights and none of the Ordinary Shares are held in treasury. The total number of voting rights in the Company immediately following Admission will therefore be 5,224,860.
For further information please contact:
Bioventix plc |
| Tel: 01252 728 001 |
Peter Harrison | Chief Executive Officer | |
Bruce Hiscock | Chief Financial Officer | |
Cavendish Capital Markets Limited |
| Tel: 020 7220 0500 |
Geoff Nash / Elysia Bough | Corporate Finance | |
Nigel Birks / Harriet Ward | ECM |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||
a. | Name of PDMR | Peter Harrison | ||||||
2 | Reason for notification
| |||||||
a. | Position/Status | Chief Executive Officer | ||||||
b. | Initial notification/ Amendment | Initial notification | ||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a. | Name | Bioventix plc | ||||||
b. | LEI | 213800225MHX7LZQY108 | ||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a. | Description of the financial instrument, type of instrument Identification Code | Ordinary Shares of 5 pence each
GB00B4QVDF07
| ||||||
b. | Nature of the transaction | Exercise of Options over Ordinary Shares | ||||||
c. | Price(s) and volume(s)
|
| ||||||
d. | Aggregated information
- Aggregated Volume
- Price |
See above | ||||||
e. | Date of the transaction | 10 April 2025
| ||||||
f. | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||||
Related Shares:
Bioventix